Home
Clinical Trials
The Efficacy, Safety and Gene...

The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients

Last Updated: 2008-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-30

Study Completion Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nifedipine and barnidipine act as calcium channel blockers, and are widely prescribed for pressure control of prehypertension and stage 1 hypertension.

CYP3A4 is responsible for the metabolism of nifedipine and nifedipine, while the contribution of CYP3A5 remains ambiguous. This study is aimed to analyze the association between antihypertensive effects of nifedipine as well as barnidipine and single nucleotide polymorphisms of CYP3A4, CYP3A5 and calcium channels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients

NCT00338338

Uncomplicated Hypertension Hypertension Essential

COMPLETED PHASE4

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

NCT03217825

Hypertension

COMPLETED PHASE2

Amlodipine Prevents Morning Blood Pressure Surge Study

NCT01030081

Hypertension

COMPLETED PHASE4

Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study

NCT00768560

Hypertension

COMPLETED PHASE2

Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension

NCT01518855

Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For each drug, 20 patients will be enrolled. Patients' blood pressure and heart rates will be measured at first visit, followed by visits at week4 , week 8 and week 12. Blood samples will be drawn at week 4 and week 12 for following analyses of drug plasma concentrations. SNPs in CYP3A4, CYP3A5 and calcium channel v 1.2 will be genotyped using SNPstream.

The differences in the decrease of blood pressures and the durg plasma concentrations between genotypes will be analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 20\~90 years old patient
* mild to moderate hypertensive patients
* can finish this study
* can sign agreement

Exclusion Criteria

* severe hypertension
* Heart failure, Arrhythmia
* Liver or kidney failure
* pregnant women
* allergy to dihydropyridines
* attend other clinical trials in past 3 month

Minimum Eligible Age

22 Years

Maximum Eligible Age

87 Years

Eligible Sex

ALL

Accepts Healthy Volunteers